GDF2026 - Office of Pharmaceutical Quality (OPQ) Keynote
An FDA presenter reviewed Office of Pharmaceutical Quality and Office of Generic Drugs initiatives, outlining the new PreCheck program, nitrosamine mitigation efforts, the Quality Management Maturity assessments, use of AI and CASA in reviews, and CDER research supporting generic drug access and cost savings.
AI-Generated Content
The text on this page is AI generated. Summaries, highlights, analysis, and video transcripts are all produced from the original source material.
AI can make mistakes, so if you spot one, and we will fix it for everyone.
Note: the source content is unaltered by us. Any content source we link to, be it a video, an audio recording, or a document, is presented exactly as its publisher released it. That publisher is usually a government body, sometimes an individual official or another organisation.
No transcript available.
